Search for "BINOL" in Full Text gives 77 result(s) in Beilstein Journal of Organic Chemistry.
Beilstein J. Org. Chem. 2015, 11, 1274–1331, doi:10.3762/bjoc.11.142
Graphical Abstract
Figure 1: General representation of cyclophanes.
Figure 2: cyclophanes one or more with heteroatom.
Figure 3: Metathesis catalysts 12–17 and C–C coupling catalyst 18.
Figure 4: Natural products containing the cyclophane skeleton.
Figure 5: Turriane family of natural products.
Scheme 1: Synthesis of [3]ferrocenophanes through Mannich reaction. Reagents and conditions: (i) excess HNMe2...
Scheme 2: Synthesis of cyclophanes through Michael addition. Reagents and conditions: (i) xylylene dibromide,...
Scheme 3: Synthesis of normuscopyridine analogue 37 through an oxymercuration–oxidation strategy. Reagents an...
Scheme 4: Synthesis of tribenzocyclotriyne 39 through Castro–Stephens coupling reaction. Reagents and conditi...
Scheme 5: Synthesis of cyclophane 43 through Glaser–Eglinton coupling. Reagents and conditions: (i) 9,10-bis(...
Scheme 6: Synthesis of the macrocyclic C-glycosyl cyclophane through Glaser coupling. Reagents and conditions...
Scheme 7: Synthesis of cyclophane-containing complex 49 through Glaser–Eglinton coupling reaction. Reagents a...
Scheme 8: Synthesis of cyclophane 53 through Glaser–Eglinton coupling. Reagents and conditions: (i) K2CO3, ac...
Figure 6: Cyclophanes 54–56 that have been synthesized through Glaser–Eglinton coupling.
Figure 7: Synthesis of tetrasubstituted [2.2]paracyclophane 57 and chiral cyclophyne 58 through Eglinton coup...
Scheme 9: Synthesis of cyclophane through Glaser–Hay coupling reaction. Reagents and conditions: (i) CuCl2 (1...
Scheme 10: Synthesis of seco-C/D ring analogs of ergot alkaloids through intramolecular Heck reaction. Reagent...
Scheme 11: Synthesis of muscopyridine 73 via Kumada coupling. Reagents and conditions: (i) 72, THF, ether, 20 ...
Scheme 12: Synthesis of the cyclophane 79 via McMurry coupling. Reagents and conditions: (i) 75, decaline, ref...
Scheme 13: Synthesis of stilbenophane 81 via McMurry coupling. Reagents and conditions: (i) TiCl4, Zn, pyridin...
Scheme 14: Synthesis of stilbenophane 85 via McMurry coupling. Reagents and conditions: (i) NBS (2 equiv), ben...
Figure 8: List of cyclophanes prepared via McMurry coupling reaction as a key step.
Scheme 15: Synthesis of paracyclophane by cross coupling involving Pd(0) catalyst. Reagents and conditions: (i...
Scheme 16: Synthesis of the cyclophane 112 via the pinacol coupling and 113 by RCM. Reagents and conditions: (...
Scheme 17: Synthesis of cyclophane derivatives 122a–c via Sonogoshira coupling. Reagents and conditions: (i) C...
Scheme 18: Synthesis of cyclophane 130 via Suzuki–Miyaura reaction as a key step. Reagents and conditions: (i)...
Scheme 19: Synthesis of the mycocyclosin via Suzuki–Miyaura cross coupling. Reagents and conditions: (i) benzy...
Scheme 20: Synthesis of cyclophanes via Wurtz coupling reaction Reagents and conditions: (i) PhLi, Et2O, C6H6,...
Scheme 21: Synthesis of non-natural glycophanes using alkyne metathesis. Reagents and conditions: (i) G-I (12)...
Figure 9: Synthesis of cyclophanes via ring-closing alkyne metathesis.
Scheme 22: Synthesis of crownophanes by cross-enyne metathesis. Reagents and conditions: (i) G-II (13), 5 mol ...
Scheme 23: Synthesis of (−)-cylindrocyclophanes A (156) and (−)-cylindrocyclophanes F (155). Reagents and cond...
Scheme 24: Synthesis of cyclophane 159 derivatives via SM cross-coupling and RCM. Reagents and conditions: (i)...
Scheme 25: Sexithiophene synthesis via cross metathesis. Reagents and conditions: (i) 161, Pd(PPh3)4, K2CO3, T...
Scheme 26: Synthesis of pyrrole-based cyclophane using enyne metathesis. Reagents and conditions: (i) Se, chlo...
Scheme 27: Synthesis of macrocyclic derivatives by RCM. Reagents and conditions: (i) G-I/G-II, CH2Cl2, 0.005 M...
Scheme 28: Synthesis of enantiopure β-lactam-based dienyl bis(dihydrofuran) 179. Reagents and conditions: (i) ...
Scheme 29: Synthesis of a [1.1.6]metaparacyclophane derivative 183 via SM cross coupling. Reagents and conditi...
Scheme 30: Synthesis of a [1.1.6]metaparacyclophane derivative 190 via SM cross coupling. Reagents and conditi...
Scheme 31: Template-promoted synthesis of cyclophanes involving RCM. Reagents and conditions: (i) acenaphthene...
Scheme 32: Synthesis of [3.4]cyclophane derivatives 200 via SM cross coupling and RCM. Reagents and conditions...
Figure 10: Examples for cyclophanes synthesized by RCM.
Scheme 33: Synthesis of the longithorone C framework assisted by fluorinated auxiliaries. Reagents and conditi...
Scheme 34: Synthesis of the longithorone framework via RCM. Reagents and conditions: (i) 213, NaH, THF, rt, 10...
Scheme 35: Synthesis of floresolide B via RCM as a key step. Reagents and conditions: (i) G-II (13, 0.1 equiv)...
Scheme 36: Synthesis of normuscopyridine (223) by the RCM strategy. Reagents and condition: (i) Mg, THF, hexen...
Scheme 37: Synthesis of muscopyridine (73) via RCM. Reagents and conditions: (i) 225, NaH, THF, 0 °C to rt, 1....
Scheme 38: Synthesis of muscopyridine (73) via RCM strategy. Reagents and conditions: (i) NaH, n-BuLi, 5-bromo...
Scheme 39: Synthesis of pyridinophane derivatives 223 and 245. Reagents and conditions: (i) PhSO2Na, TBAB, CH3...
Scheme 40: Synthesis of metacyclophane derivatives 251 and 253. Reagents and conditions: (i) 240, NaH, THF, rt...
Scheme 41: Synthesis of normuscopyridine and its higher analogues. Reagents and conditions: (i) alkenyl bromid...
Scheme 42: Synthesis of fluorinated ferrocenophane 263 via a [2 + 2] cycloaddition. Reagents and conditions: (...
Scheme 43: Synthesis of [2.n]metacyclophanes 270 via a [2 + 2] cycloaddition. Reagents and conditions: (i) Ac2...
Scheme 44: Synthesis of metacyclophane 273 by a [2 + 2 + 2] co-trimerization. Reagents and conditions: (i) [Rh...
Scheme 45: Synthesis of paracyclophane 276 via a [2 + 2 + 2] cycloaddition reaction. Reagents and conditions: ...
Scheme 46: Synthesis of cyclophane 278 via a [2 + 2 + 2] cycloaddition reaction. Reagents and conditions: (i) ...
Scheme 47: Synthesis of cyclophane 280 via a [2 + 2 + 2] cycloaddition. Reagents and conditions: (i) [(Rh(cod)(...
Scheme 48: Synthesis of taxane framework by a [2 + 2 + 2] cycloaddition. Reagents and conditions: (i) Cp(CO)2 ...
Scheme 49: Synthesis of cyclophane 284 and 285 via a [2 + 2 + 2] cycloaddition reaction. Reagents and conditio...
Scheme 50: Synthesis of pyridinophanes 293a,b and 294a,b via a [2 + 2 + 2] cycloaddition. Reagents and conditi...
Scheme 51: Synthesis of pyridinophanes 296 and 297 via a [2 + 2 + 2] cycloaddition. Reagents and conditions: (...
Scheme 52: Synthesis of triazolophane by a 1,3-dipolar cycloaddition. Reagents and conditions: (i) propargyl b...
Scheme 53: Synthesis of glycotriazolophane 309 by a click reaction. Reagents and conditions: (i) LiOH, H2O, Me...
Figure 11: Cyclophanes 310 and 311 prepared via click chemistry.
Scheme 54: Synthesis of cyclophane via the Dötz benzannulation. Reagents and conditions: (i) THF, 100 °C, 12 h...
Scheme 55: Synthesis of [6,6]metacyclophane by a Dötz benzannulation. Reagents and conditions: (i) THF, 100 °C...
Scheme 56: Synthesis of cyclophanes by a Dötz benzannulation. Reagents and conditions: (i) THF, 65 °C, 3 h; (i...
Scheme 57: Synthesis of muscopyridine (73) via an intramolecular DA reaction of ketene. Reagents and condition...
Scheme 58: Synthesis of bis[10]paracyclophane 336 via Diels–Alder reaction. Reagents and conditions: (i) DMAD,...
Scheme 59: Synthesis of [8]paracyclophane via DA reaction. Reagents and conditions: (i) maleic anhydride, 3–5 ...
Scheme 60: Biomimetic synthesis of (−)-longithorone A. Reagents and conditions: (i) Me2AlCl, CH2Cl2, −20 °C, 7...
Scheme 61: Synthesis of sporolide B (349) via a [4 + 2] cycloaddition reaction. Reagents and conditions: (i) P...
Scheme 62: Synthesis of the framework of (+)-cavicularin (352) via a [4 + 2] cycloaddition. Reagents and condi...
Scheme 63: Synthesis of oxazole-containing cyclophane 354 via Beckmann rearrangement. Reagents and conditions:...
Scheme 64: Synthesis of cyclophanes 360a–c via benzidine rearrangement. Reagents and conditions: (i) 356a–d, K2...
Scheme 65: Synthesis of cyclophanes 365a–c via benzidine rearrangement. Reagents and conditions: (i) BocNHNH2,...
Scheme 66: Synthesis of metacyclophane 367 via Ciamician–Dennstedt rearrangement. Reagents and conditions: (i)...
Scheme 67: Synthesis of cyclophane by tandem Claisen rearrangement and RCM as key steps. Reagents and conditio...
Scheme 68: Synthesis of cyclophane derivative 380. Reagents and conditions: (i) K2CO3, CH3CN, allyl bromide, r...
Scheme 69: Synthesis of metacyclophane via Cope rearrangement. Reagents and conditions: (i) MeOH, NaBH4, rt, 1...
Scheme 70: Synthesis of cyclopropanophane via Favorskii rearrangement. Reagents and conditions: (i) Br2, CH2Cl2...
Scheme 71: Cyclophane 389 synthesis via photo-Fries rearrangement. Reagents and conditions: (i) DMAP, EDCl/CHCl...
Scheme 72: Synthesis of normuscopyridine (223) via Schmidt rearrangement. Reagents and conditions: (i) ethyl s...
Scheme 73: Synthesis of crownophanes by tandem Claisen rearrangement. Reagents and conditions: (i) diamine, Et3...
Scheme 74: Attempted synthesis of cyclophanes via tandem Claisen rearrangement and RCM. Reagents and condition...
Scheme 75: Synthesis of muscopyridine via alkylation with 2,6-dimethylpyridine anion. Reagents and conditions:...
Scheme 76: Synthesis of cyclophane via Friedel–Craft acylation. Reagents and conditions: (i) CS2, AlCl3, 7 d, ...
Scheme 77: Pyridinophane 418 synthesis via Friedel–Craft acylation. Reagents and conditions: (i) 416, AlCl3, CH...
Scheme 78: Cyclophane synthesis involving the Kotha–Schölkopf reagent 421. Reagents and conditions: (i) NBS, A...
Scheme 79: Cyclophane synthesis involving the Kotha–Schölkopf reagent 421. Reagents and conditions: (i) BEMP, ...
Scheme 80: Cyclophane synthesis by coupling with TosMIC. Reagents and conditions: (i) (a) ClCH2OCH3, TiCl4, CS2...
Scheme 81: Synthesis of diaza[32]cyclophanes and triaza[33]cyclophanes. Reagents and conditions: (i) DMF, NaH,...
Scheme 82: Synthesis of cyclophane 439 via acyloin condensation. Reagents and conditions: (i) Na, xylene, 75%;...
Scheme 83: Synthesis of multibridged binuclear cyclophane 442 by aldol condensation. Reagents and conditions: ...
Scheme 84: Synthesis of various macrolactones. Reagents and conditions: (i) iPr2EtN, DMF, 77–83%; (ii) TBDMSCl...
Scheme 85: Synthesis of muscone and muscopyridine via Yamaguchi esterification. Reagents and conditions: (i) 4...
Scheme 86: Synthesis of [5]metacyclophane via a double elimination reaction. Reagents and conditions: (i) LiBr...
Figure 12: Cyclophanes 466–472 synthesized via Hofmann elimination.
Scheme 87: Synthesis of cryptophane via Baylis–Hillman reaction. Reagents and conditions: (i) methyl acrylate,...
Scheme 88: Synthesis of cyclophane 479 via double Chichibabin reaction. Reagents and conditions: (i) excess 478...
Scheme 89: Synthesis of cyclophane 483 via double Chichibabin reaction. Reagents and conditions: (i) 481, OH−;...
Scheme 90: Synthesis of cyclopeptide via an intramolecular SNAr reaction. Reagents and conditions: (i) TBAF, T...
Scheme 91: Synthesis of muscopyridine (73) via C-zip ring enlargement reaction. Reagents and conditions: (i) H...
Figure 13: Mechanism of the formation of compound 494.
Scheme 92: Synthesis of indolophanetetraynes 501a,b using the Nicholas reaction as a key step. Reagents and co...
Scheme 93: Synthesis of cyclophane via radical cyclization. Reagents and conditions: (i) cyclododecanone, phen...
Scheme 94: Synthesis of (−)-cylindrocyclophanes A (156) and (−)-cylindrocyclophanes F (155). Reagents and cond...
Scheme 95: Cyclophane synthesis via Wittig reaction. Reagents and conditions: (i) LiOEt (2.1 equiv), THF, −78 ...
Figure 14: Representative examples of cyclophanes synthesized via Wittig reaction.
Scheme 96: Synthesis of the [6]paracyclophane via isomerization of Dewar benzene. Reagents and conditions: (i)...
Beilstein J. Org. Chem. 2015, 11, 530–562, doi:10.3762/bjoc.11.60
Graphical Abstract
Scheme 1: Generic mechanism for the conjugate addition reaction.
Figure 1: Methods to activate unsaturated amide/lactam systems.
Scheme 2: DCA of Grignard reagents to an L-ephedrine derived chiral α,β–unsaturated amide.
Figure 2: Chiral auxiliaries used in DCA reactions.
Scheme 3: Comparison between auxiliary 5 and the Oppolzer auxiliary in a DCA reaction.
Scheme 4: Use of Evans auxiliary in a DCA reaction.
Figure 3: Lewis acid complex of the Evans auxiliary [43].
Scheme 5: DCA reactions of α,β-unsaturated amides utilizing (S,S)-(+)-pseudoephedrine and the OTBS-derivative...
Figure 4: Proposed model accounting for the diastereoselectivity observed in the 1,4-addition of Bn2NLi to α,...
Scheme 6: An example of a tandem conjugate addition–α-alkylation reaction of an α,β-unsaturated amide utilizi...
Scheme 7: Conjugate addition to an α,β-unsaturated bicyclic lactam leading to (+)-paroxetine and (+)-femoxeti...
Scheme 8: Intramolecular conjugate addition reaction to α,β-unsaturated amide.
Scheme 9: Conjugate addition to an α,β-unsaturated pyroglutamate derivative.
Scheme 10: Cu(I)–NHC-catalyzed asymmetric silylation of α,β-unsaturated lactams and amides.
Scheme 11: Asymmetric copper-catalyzed 1,4-borylation of an α,β-unsaturated amide.
Scheme 12: Asymmetric cross-coupling 49 to phenyl chloride.
Scheme 13: Rhodium-catalyzed asymmetric 1,4-arylation of an α,β-unsaturated lactam.
Scheme 14: Rhodium-catalyzed asymmetric 1,4-arylation of an α,β-unsaturated amide.
Scheme 15: Rhodium-catalyzed asymmetric 1,4-arylation of an α,β-unsaturated amide using a chiral bicyclic dien...
Scheme 16: Synthesis of (R)-(−)-baclofen through a rhodium-catalyzed asymmetric 1,4-arylation of lactam 58.
Scheme 17: Rhodium-catalyzed asymmetric 1,4-arylation of an α,β-unsaturated amide and lactam employing organo[...
Scheme 18: Rhodium-catalyzed asymmetric 1,4-arylation of an α,β-unsaturated lactam employing benzofuran-2-ylzi...
Figure 5: Further chiral ligands that have been used in rhodium-catalyzed 1,4-additions of α,β-unsaturated am...
Scheme 19: Palladium-catalyzed asymmetric 1,4-arylation of arylsiloxanes to a α,β-unsaturated lactam.
Scheme 20: SmI2-mediated cyclization of α,β-unsaturated Weinreb amides.
Figure 6: Chiral Lewis acid complexes used in the Mukaiyama–Michael addition of α,β-unsaturated amides.
Scheme 21: Mukaiyama–Michael addition of thioester silylketene acetal to α,β-unsaturated N-alkenoyloxazolidino...
Scheme 22: Asymmetric 1,4-addition of aryl acetylides to α,β-unsaturated thioamides.
Scheme 23: Asymmetric 1,4-addition of alkyl acetylides to α,β-unsaturated thioamides.
Scheme 24: Asymmetric vinylogous conjugate additions of unsaturated butyrolactones to α,β-unsaturated thioamid...
Scheme 25: Gd-catalyzed asymmetric 1,4-cyanation of α,β-unsaturated N-acylpyrroles [205].
Scheme 26: Lewis acid-catalyzed asymmetric 1,4-cyanation of α,β-unsaturated N-acylpyrazole 107.
Scheme 27: Lewis acid mediated 1,4-addition of dibenzyl malonate to α,β-unsaturated N-acylpyrroles.
Scheme 28: Chiral Lewis acid mediated 1,4-radical addition to α,β-unsaturated N-acyloxazolidinone [224].
Scheme 29: Aza-Michael addition of O-benzylhydroxylamine to an α,β-unsaturated N-acylpyrazole.
Scheme 30: An example of the aza-Michael addition of secondary aryl amines to an α,β-unsaturated N-acyloxazoli...
Scheme 31: Aza-Michael additions of anilines to a α,β-unsaturated N-alkenoyloxazolidinone catalyzed by palladi...
Scheme 32: Aza-Michael additions of aniline to an α,β-unsaturated N-alkenoylbenzamide and N-alkenoylcarbamate ...
Scheme 33: Difference between aza-Michael addition ran using the standard protocol versus the slow addition pr...
Scheme 34: Aza-Michael additions of aryl amines salts to an α,β-unsaturated N-alkenoyloxazolidinone catalyzed ...
Scheme 35: Aza-Michael addition of N-alkenoyloxazolidiniones catalyzed by samarium diiodide [244].
Scheme 36: Asymmetric aza-Michael addition of p-anisidine to α,β-unsaturated N-alkenoyloxazolidinones catalyze...
Scheme 37: Asymmetric aza-Michael addition of O-benzylhydroxylamine to N-alkenoyloxazolidinones catalyzed by i...
Scheme 38: Asymmetric 1,4-addition of purine to an α,β-unsaturated N-alkenoylbenzamide catalyzed by (S,S)-(sal...
Scheme 39: Asymmetric 1,4-addition of phosphites to α,β-unsaturated N-acylpyrroles.
Scheme 40: Asymmetric 1,4-addition of phosphine oxides to α,β-unsaturated N-acylpyrroles.
Scheme 41: Tandem Michael-aldol reaction catalyzed by a hydrogen-bonding organocatalyst.
Scheme 42: Examples of the sulfa-Michael–aldol reaction employing α,β-unsaturated N-acylpyrazoles.
Scheme 43: Example of the sulfa-Michael addition of α,β-unsaturated N-alkenoyloxazolidinones.
Figure 7: Structure of cinchona alkaloid-based squaramide catalyst.
Scheme 44: Asymmetric intramolecular oxa-Michael addition of an α,β-unsaturated amide.
Scheme 45: Formal synthesis atorvastatin.
Beilstein J. Org. Chem. 2014, 10, 1638–1644, doi:10.3762/bjoc.10.170
Graphical Abstract
Scheme 1: SNVin reactions of pentachloro-2-nitro-1,3-butadiene (1).
Scheme 2: Formation of thiazolidin-4-ones 7–19.
Figure 1: Hindered rotation in the case of ortho- or meta-substituted aniline precursors.
Figure 2: X-ray analysis of thiazolidin-4-one 11.
Scheme 3: Assumed mechanism for the formation of thiazolidin-4-ones 7–18.
Scheme 4: Substitution reactions of the precursors 3 and 5 with additional amines.
Scheme 5: Synthesis of 5-arylmethylidenethiazolidin-4-ones 22–26 and 1H-pyrazoles 27, 28.
Scheme 6: Assumed mechanism for the formation of 1H-pyrazole 27.
Scheme 7: Formation of ethyl propanoate 29 and subsequent reactions.
Beilstein J. Org. Chem. 2014, 10, 1308–1316, doi:10.3762/bjoc.10.132
Graphical Abstract
Scheme 1: Synthesis of macrocycles 3 and 4.
Figure 1: 1H NMR spectra of macrocycles 3a–d, with key proton resonances for the spacing units and key benzyl...
Figure 2: 1H NMR spectroscopy of macrocycles 4a–d, with proton resonances for the spacing units and key benzy...
Figure 3: CD spectra of macrocycles 3b, 3d, 4b, 4d in EtOH (0.5–12 × 10−6 M).
Figure 4: UV–vis titration of C60 (1.8 × 10−4 M) in toluene with increasing amounts of macrocycle 4b (top) an...
Beilstein J. Org. Chem. 2014, 10, 432–441, doi:10.3762/bjoc.10.40
Graphical Abstract
Scheme 1: Synthesis of ligands 3 and 6.
Figure 1: ESI mass spectrum (positive mode) of an 1:1 mixture of (R)-3 and [(dppp)Pd(OTf)2] in acetone.
Figure 2: 1H NMR spectra (500.1 MHz, in CD2Cl2/CD3CN 3:1 at 298 K) of a) a 1:1 mixture of [Pd(dppp)]OTf2 and (...
Figure 3: 31P NMR spectra of a) a 1:1 mixture of [Pd(dppp)]OTf2 and (R)-3, b) a 1:1 mixture of [Pd(dppp)]OTf2...
Figure 4: ESI mass spectrum (positive mode) of an 1:1:2 mixture of (R)-3, (S)-6, and [(dppp)Pt(OTf)2] in acet...
Figure 5: Single crystal X-ray structure analysis of [(dppp)2Pd2{(R)-3}2][(dppp)2Pd2{(S)-3}2](OTf)8 obtained ...
Beilstein J. Org. Chem. 2014, 10, 224–236, doi:10.3762/bjoc.10.18
Graphical Abstract
Figure 1: Thiourea, squaramide, P-triamide and cyclodiphosphazane with computed distances between H-atoms.
Figure 2: Urea, squaramide, P-triamide and cyclodiphosphazane coordinated to nitrobenzene, with the computed ...
Scheme 1: Chiral PV-amide catalysts based on BINOL and chinchona backbones.
Scheme 2: Exclusive formation of the mono- and trisubstituted product from thiophosphoryl chloride and anilin...
Figure 3: X-ray structure of 6-dimer. The hydrogen atoms are omitted for clarity, except at all nitrogens.
Figure 4: X-ray structure of 7a-dimer. The hydrogen atoms are omitted for clarity, except at all nitrogens.
Scheme 3: Synthesis of chiral cyclodiphosphazane catalysts 14a/b, 15 and 16.
Figure 5: X-ray structure of 14a. The hydrogen atoms are omitted for clarity, except at nitrogen.
Figure 6: 31P{1H} NMR spectrum in CDCl3 at rt showing C2 symmetry of 14a at rt.
Figure 7: X-ray structure of 15. The hydrogen atoms are omitted for clarity, except at nitrogen.
Figure 8: X-ray structure of 16. The hydrogen atoms are omitted for clarity, except at nitrogen.
Figure 9: Enantiodetermining transition states TS-14a/TS-14b arising from the addition of 2-hydroxynapthoquin...
Beilstein J. Org. Chem. 2013, 9, 2457–2462, doi:10.3762/bjoc.9.284
Graphical Abstract
Scheme 1: Photocyclization–reduction of 2-aminochalcone.
Scheme 2: Experimental setup of continuous-flow photocyclization–reduction cascade.
Beilstein J. Org. Chem. 2013, 9, 2265–2319, doi:10.3762/bjoc.9.265
Graphical Abstract
Scheme 1: Scaled industrial processes for the synthesis of simple pyridines.
Scheme 2: Synthesis of nicotinic acid from 2-methyl-5-ethylpyridine (1.11).
Scheme 3: Synthesis of 3-picoline and nicotinic acid.
Scheme 4: Synthesis of 3-picoline from 2-methylglutarodinitrile 1.19.
Scheme 5: Picoline-based synthesis of clarinex (no yields reported).
Scheme 6: Mode of action of proton-pump inhibitors and structures of the API’s.
Scheme 7: Hantzsch-like route towards the pyridine rings in common proton pump inhibitors.
Figure 1: Structures of rosiglitazone (1.40) and pioglitazone (1.41).
Scheme 8: Synthesis of rosiglitazone.
Scheme 9: Syntheses of 2-pyridones.
Scheme 10: Synthesis and mechanism of 2-pyrone from malic acid.
Scheme 11: Polymer-assisted synthesis of rosiglitazone.
Scheme 12: Synthesis of pioglitazone.
Scheme 13: Meerwein arylation reaction towards pioglitazone.
Scheme 14: Route towards pioglitazone utilising tyrosine.
Scheme 15: Route towards pioglitazone via Darzens ester formation.
Scheme 16: Syntheses of the thiazolidinedione moiety.
Scheme 17: Synthesis of etoricoxib utilising Negishi and Stille cross-coupling reactions.
Scheme 18: Synthesis of etoricoxib via vinamidinium condensation.
Figure 2: Structures of nalidixic acid, levofloxacin and moxifloxacin.
Scheme 19: Synthesis of moxifloxacin.
Scheme 20: Synthesis of (S,S)-2,8-diazabicyclo[4.3.0]nonane 1.105.
Scheme 21: Synthesis of levofloxacin.
Scheme 22: Alternative approach to the levofloxacin core 1.125.
Figure 3: Structures of nifedipine, amlodipine and clevidipine.
Scheme 23: Mg3N2-mediated synthesis of nifedipine.
Scheme 24: Synthesis of rac-amlodipine as besylate salt.
Scheme 25: Aza Diels–Alder approach towards amlodipine.
Scheme 26: Routes towards clevidipine.
Figure 4: Examples of piperidine containing drugs.
Figure 5: Discovery of tiagabine based on early leads.
Scheme 27: Synthetic sequences to tiagabine.
Figure 6: Structures of solifenacin (2.57) and muscarine (2.58).
Scheme 28: Enantioselective synthesis of solifenacin.
Figure 7: Structures of DPP-4 inhibitors of the gliptin-type.
Scheme 29: Formation of inactive diketopiperazines from cis-rotameric precursors.
Figure 8: Co-crystal structure of carmegliptin bound in the human DPP-4 active site (PDB 3kwf).
Scheme 30: Improved route to carmegliptin.
Figure 9: Structures of lamivudine and zidovudine.
Scheme 31: Typical routes accessing uracil, thymine and cytosine.
Scheme 32: Coupling between pyrimidones and riboses via the Vorbrüggen nucleosidation.
Scheme 33: Synthesis of lamivudine.
Scheme 34: Synthesis of raltegravir.
Scheme 35: Mechanistic studies on the formation of 3.22.
Figure 10: Structures of selected pyrimidine containing drugs.
Scheme 36: General preparation of pyrimidines and dihydropyrimidones.
Scheme 37: Synthesis of imatinib.
Scheme 38: Flow synthesis of imatinib.
Scheme 39: Syntheses of erlotinib.
Scheme 40: Synthesis of erlotinib proceeding via Dimroth rearrangement.
Scheme 41: Synthesis of lapatinib.
Scheme 42: Synthesis of rosuvastatin.
Scheme 43: Alternative preparation of the key aldehyde towards rosuvastatin.
Figure 11: Structure comparison between nicotinic acetylcholine receptor agonists.
Scheme 44: Syntheses of varenicline and its key building block 4.5.
Scheme 45: Synthetic access to eszopiclone and brimonidine via quinoxaline intermediates.
Figure 12: Bortezomib bound in an active site of the yeast 20S proteasome ([114], pdb 2F16).
Scheme 46: Asymmetric synthesis of bortezomib.
Figure 13: Structures of some prominent piperazine containing drugs.
Figure 14: Structural comparison between the core of aplaviroc (4.35) and a type-1 β-turn (4.36).
Scheme 47: Examplary synthesis of an aplaviroc analogue via the Ugi-MCR.
Scheme 48: Syntheses of azelastine (5.1).
Figure 15: Structures of captopril, enalapril and cilazapril.
Scheme 49: Synthesis of cilazapril.
Figure 16: Structures of lamotrigine, ceftriaxone and azapropazone.
Scheme 50: Synthesis of lamotrigine.
Scheme 51: Alternative synthesis of lamotrigine (no yields reported).
Figure 17: Structural comparison between imiquimod and the related adenosine nucleoside.
Scheme 52: Conventional synthesis of imiquimod (no yields reported).
Scheme 53: Synthesis of imiquimod.
Scheme 54: Synthesis of imiquimod via tetrazole formation (not all yields reported).
Figure 18: Structures of various anti HIV-medications.
Scheme 55: Synthesis of abacavir.
Figure 19: Structures of diazepam compared to modern replacements.
Scheme 56: Synthesis of ocinaplon.
Scheme 57: Access to zaleplon and indiplon.
Scheme 58: Different routes towards the required N-methylpyrazole 6.65 of sildenafil.
Scheme 59: Polymer-supported reagents in the synthesis of key aminopyrazole 6.72.
Scheme 60: Early synthetic route to sildenafil.
Scheme 61: Convergent preparations of sildenafil.
Figure 20: Comparison of the structures of sildenafil, tadalafil and vardenafil.
Scheme 62: Short route to imidazotriazinones.
Scheme 63: Alternative route towards vardenafils core imidazotriazinone (6.95).
Scheme 64: Bayer’s approach to the vardenafil core.
Scheme 65: Large scale synthesis of vardenafil.
Scheme 66: Mode of action of temozolomide (6.105) as methylating agent.
Scheme 67: Different routes to temozolomide.
Scheme 68: Safer route towards temozolomide.
Figure 21: Some unreported heterocyclic scaffolds in top market drugs.
Beilstein J. Org. Chem. 2013, 9, 2250–2264, doi:10.3762/bjoc.9.264
Graphical Abstract
Figure 1: Gold-promoted 1,2-acyloxy migration on propargylic systems.
Scheme 1: Gold-catalyzed enantioselective intermolecular cyclopropanation.
Scheme 2: Gold-catalyzed enantioselective intramolecular cyclopropanation.
Scheme 3: Gold-catalyzed cyclohepta-annulation cascade.
Scheme 4: Application to the formal synthesis of frondosin A.
Scheme 5: Gold(I)-catalyzed enantioselective cyclopropenation of alkynes.
Scheme 6: Enantioselective cyclopropanation of diazooxindoles.
Figure 2: Proposed structures for gold-activated allene complexes.
Scheme 7: Gold-catalyzed enantioselective [2 + 2] cycloadditions of allenenes.
Scheme 8: Gold-catalyzed allenediene [4 + 3] and [4 + 2] cycloadditions.
Scheme 9: Gold-catalyzed enantioselective [4 + 2] cycloadditions of allenedienes.
Scheme 10: Gold-catalyzed enantioselective [4 + 3] cycloadditions of allenedienes.
Scheme 11: Gold-catalyzed enantioselective [4 + 2] cycloadditions of allenamides.
Scheme 12: Enantioselective [2 + 2] cycloadditions of allenamides.
Scheme 13: Mechanistic rational for the gold-catalyzed [2 + 2] cycloadditions.
Scheme 14: Enantioselective cascade cycloadditions between allenamides and oxoalkenes.
Scheme 15: Enantioselective [3 + 2] cycloadditions of nitrones and allenamides.
Scheme 16: Enantioselective formal [4 + 3] cycloadditions leading to 1,2-oxazepane derivatives.
Scheme 17: Enantioselective gold(I)-catalyzed 1,3-dipolar [3 + 3] cycloaddition between 2-(1-alkynyl)-2-alken-...
Scheme 18: Enantioselective [4 + 3] cycloaddition leading to 5,7-fused bicyclic furo[3,4-d][1,2]oxazepines.
Beilstein J. Org. Chem. 2013, 9, 2224–2232, doi:10.3762/bjoc.9.261
Graphical Abstract
Figure 1: Monodentate chiral NHC gold catalysts in recent years.
Scheme 1: Synthesis of compound 9.
Scheme 2: Synthesis of N-heterocyclic carbene precursor.
Scheme 3: Synthesis of benzimidazolium salt (S)-14.
Scheme 4: Synthesis of carbene Au complexes.
Figure 2: The crystal data of gold complex (S)-15a was deposited in the CCDC with the number 883917. Empirica...
Figure 3: The crystal data of gold complex (S)-15b was deposited in the CCDC with the number 883916. Empirica...
Scheme 5: Rotamers of 1a and 1b by DFT calculation reported by Slaughter’s group.
Scheme 6: The synthesis of P–Au complexes.
Figure 4: The crystal data of gold complex (S)-18 was deposited in the CCDC with the number 920617. Empirical...
Figure 5: The crystal data of gold complex (S)-22 was deposited in the CCDC with the number 928664. Empirical...
Beilstein J. Org. Chem. 2013, 9, 1559–1564, doi:10.3762/bjoc.9.177
Graphical Abstract
Figure 1: Catalysts and seleno reagents evaluated in this study.
Figure 2: Generality for substitution at the indoline moiety. The reaction was performed in 0.1 mmol scale in...
Figure 3: X-ray crystallography of 4a catalyzed by (S)-3b.
Scheme 1: The plausible reaction mechanism.
Scheme 2: Scale up of the protocol and synthetic application.
Beilstein J. Org. Chem. 2012, 8, 1819–1824, doi:10.3762/bjoc.8.208
Graphical Abstract
Scheme 1: Brønsted acid catalyzed aza-Diels–Alder reaction of cyclic C-acylimines with cyclopentadiene.
Beilstein J. Org. Chem. 2012, 8, 1279–1283, doi:10.3762/bjoc.8.144
Graphical Abstract
Scheme 1: Working hypothesis: Decarboxylative Mannich reaction.
Beilstein J. Org. Chem. 2012, 8, 1241–1245, doi:10.3762/bjoc.8.139
Graphical Abstract
Scheme 1: Allylic amination of MBH carbonates of isatins to access 3-amino-2-oxindoles.
Scheme 2: Synthetic transformations of multifunctional product 4d.
Beilstein J. Org. Chem. 2012, 8, 967–976, doi:10.3762/bjoc.8.109
Graphical Abstract
Figure 1: Structure of the macrocycle (R,R)-1 (top), and synthetic strategies for the production of novel ami...
Scheme 1: Reagents and conditions: (i) SOCl2, CHCl3 or (COCl)2, DMF, CH2Cl2 then amine, Et3N, CH2Cl2 or (ii) ...
Scheme 2: Structure and synthesis of the macrocycles discussed in this paper.
Figure 2: UV and CD (EtOH) spectra of macrocycles (R,R)-10, (R,R)-11 and (R,R)-12 in the range 220–400 nm.
Figure 3: Minimized molecular structures of (from top left to bottom left, clockwise): (R,R)-10, (R,R)-11, (R,...
Figure 4: Aromatic region of the 1H NMR (CDCl3, 500 MHz, 25 °C) spectra of macrocycle (R,R)-12 (2.8 mM, botto...
Beilstein J. Org. Chem. 2012, 8, 658–661, doi:10.3762/bjoc.8.73
Graphical Abstract
Scheme 1: Plausible mechanism for Tf2NH-catalyzed isomerization of silyl enol ethers.
Scheme 2: Regioselective formation of bicyclo[4.2.0]octanes from the same substrates by the isomerization–(2 ...
Scheme 3: Formation of bicyclo[5.2.0]octane from the regioisomeric mixture of silyl enol ethers.
Beilstein J. Org. Chem. 2011, 7, 1421–1435, doi:10.3762/bjoc.7.166
Graphical Abstract
Figure 1: Fluorinated substances of biomedical relevance.
Scheme 1: Enantioselective electrophilic fluorination catalyzed by TADDOLates K1, K2. TADDOL = α,α,α',α'-tetr...
Scheme 2: Halogenation of β-ketocarbonyl compounds: Importance of enolization and the potential role of a met...
Figure 2: Model substrates for catalytic fluorinations, with the degree of enolization determined by 1H NMR m...
Figure 3: 1H NMR (250 MHz) spectra of fluorination reaction mixtures diluted with CDCl3 and filtered. a) Full...
Scheme 3: Qualitative ordering of catalytic activity of several Lewis acids in the fluorination 1→1-F.
Scheme 4: Catalysis of the “neutral” fluorination of β-ketoesters with F–TEDA by Lewis acidic titanium comple...
Figure 4: Structure of the chiral ansa-metallocene [(EBTHI)Ti(OTf)2].
Figure 5: Electrophilic fluorinating reagents of the N–F-type. F–TEDA [27]; NFTh = 1-fluoro-4-hydroxy-1,4-diazoni...
Scheme 5: Synthesis of trifluoromethyl-substituted TADDOL ligands.
Scheme 6: Correlation experiments for the assignment of absolute configuration to fluorination products 11-F, ...
Scheme 7: Mechanistic scheme proposed, based on visual and spectroscopic observations. L = solvent, counterio...
Figure 6: 1H NMR spectra of a species of the type A, generated in CD3CN solution from K1 by ionization in the...
Figure 7: Steric model explaining the face selectivity observed in the titanium–TADDOLate complex catalyzed f...
Figure 8: Excerpt from the X-ray structure of a catalyst/substrate complex [Ti(1-naphthyl-TADDOLato)(β-ketoen...
Beilstein J. Org. Chem. 2011, 7, 1315–1322, doi:10.3762/bjoc.7.154
Graphical Abstract
Figure 1: Chiral diols useful for asymmetric synthesis and the tetralithio intermediate 8.
Scheme 1: Directed ortho,ortho'-dimetalation of (R,R)-hydrobenzoin (3).
Figure 2: Percentage of (R,R)-hydrobenzoin (3) (○), monodeuterohydrobenzoin (13) (■), and dideuterohydrobenzo...
Figure 3: Percentage of methylhydrobenzoin (14) (■), and dimethylhydrobenzoin (15) (Δ) as determined by 1H NM...
Scheme 2: Formation of the tetralithio intermediate 8 and the X-ray crystal structure of the bis(siloxane) 19....
Scheme 3: Reaction of the tetralithio intermediate 8 with various electrophiles.
Scheme 4: Reactions of the diiodohydrobenzoin 12 and X-ray crystal structure of the dihydrosilepin 31.
Scheme 5: Cross coupling reactions of the bis(benzoxaborol) 20 and a short formal synthesis of (R,R)-Vivol (4...
Beilstein J. Org. Chem. 2011, 7, 555–564, doi:10.3762/bjoc.7.64
Graphical Abstract
Figure 1: Monodentate NHCs with sterically hindered N-substituents.
Figure 2: NHCs with axially chiral biaryl frameworks.
Scheme 1: Synthesis of N-heterocyclic carbene precursor.
Scheme 2: Synthesis of mono(NHC)–Pd(II) complex.
Figure 3: ORTEP drawing of NHC–Pd(II) complex (S)-7a with thermal ellipsoids at the 30% probability level. Se...
Scheme 3: Synthesis of mono(NHC)–Au(I) complex.
Figure 4: ORTEP drawing of NHC–Au(I) complex (S)-6a with thermal ellipsoids at the 30% probability level. Sel...
Scheme 4: Synthesis of mono(NHC)–Au(I) complex (S)-6b.
Scheme 5: Synthesis of mono(NHC)–Au(I) complex (S)-6c.
Scheme 6: The application of catalysts (S)-6b and 6c in the intramolecular hydroamination reaction.
Beilstein J. Org. Chem. 2011, 7, 496–502, doi:10.3762/bjoc.7.58
Graphical Abstract
Scheme 1: Synthesis of 5-aryl-11H-benzo[b]fluorenes via benzannulated enyne–allenes.
Scheme 2: Synthesis of 1,1'-binaphthyl-substituted 11H-benzo[b]fluorene 3c.
Scheme 3: Synthesis of 5-(2-methoxyphenyl)- and 5-[2-(methoxymethyl)phenyl]-11H-benzo[b]fluorene 13a and 13b.
Scheme 4: Synthesis of 5-(1-naphthyl)- and 5-(2-methoxy-1-naphthyl)-11H-benzo[b]fluorene 20a and 20b.
Scheme 5: Synthesis of 5-[2-(methoxymethyl)-1-naphthyl]-11H-benzo[b]fluorene 20c.
Scheme 6: Demethylation of 22b to form 5-(2-hydroxy-1-naphthyl)-11H-benzo[b]fluorene 24.
Beilstein J. Org. Chem. 2010, 6, No. 32, doi:10.3762/bjoc.6.32
Graphical Abstract
Figure 1: Biologically important amines and quaternary ammonium salts: histamine (1), dopamine (2) and acetyl...
Figure 2: Crown ether 18-crown-6.
Figure 3: Conformations of 18-crown-6 (4) in solvents of different polarity.
Figure 4: Binding topologies of the ammonium ion depending on the crown ring size.
Figure 5: A “pseudorotaxane” structure consisting of 24-crown-8 and a secondary ammonium ion (5); R = Ph.
Figure 6: Typical examples of azacrown ethers, cryptands and related aza macrocycles.
Figure 7: Binding of ammonium to azacrown ethers and cryptands [111-113].
Figure 8: A 19-crown-6-ether with decalino blocking groups (11) and a thiazole-dibenzo-18-crown-6-ether (12).
Figure 9: 1,3-Bis(6-oxopyridazin-1-yl)propane derivatives 13 and 14 by Campayo et al.
Figure 10: Fluorescent azacrown-PET-sensors based on coumarin.
Figure 11: Two different pyridino-cryptands (17 and 18) compared to a pyridino-crown (19); chiral ammonium ion...
Figure 12: Pyridino-18-crown-6 ligand (21), a similar acridino-18-crown-6 ligand (22) and a structurally relat...
Figure 13: Ciral pyridine-azacrown ether receptors 24.
Figure 14: Chiral 15-crown-5 receptors 26 and an analogue 18-crown-6 ligand 27 derived from amino alcohols.
Figure 15: C2-symmetric chiral 18-crown-6 amino alcohol derivatives 28 and related macrocycles.
Figure 16: Macrocycles with diamide-diester groups (30).
Figure 17: C2-symmetric chiral aza-18-crown-6 ethers (31) with phenethylamine residues.
Figure 18: Chiral C-pivot p-methoxy-phenoxy-lariat ethers.
Figure 19: Chiral lariat crown ether 34.
Figure 20: Sucrose-based chiral crown ether receptors 36.
Figure 21: Permethylated fructooligosaccharide 37 showing induced-fit chiral recognition.
Figure 22: Biphenanthryl-18-crown-6 derivative 38.
Figure 23: Chiral lariat crown ethers derived from binol by Fuji et al.
Figure 24: Chiral phenolic crown ether 41 with “aryl chiral barriers” and guest amines.
Figure 25: Chiral bis-crown receptor 43 with a meso-ternaphthalene backbone.
Figure 26: Chromogenic pH-dependent bis-crown chemosensor 44 for diamines.
Figure 27: Triamine guests for binding to receptor 44.
Figure 28: Chiral bis-crown phenolphthalein chemosensors 46.
Figure 29: Crown ether amino acid 47.
Figure 30: Luminescent receptor 48 for bis-alkylammonium guests.
Figure 31: Luminescent CEAA (49a), a bis-CEAA receptor for amino acids (49b) and the structure of lysine bindi...
Figure 32: Luminescent CEAA tripeptide for binding small peptides.
Figure 33: Bis crown ether 51a self assembles co-operatively with C60-ammonium ion 51b.
Figure 34: Triptycene-based macrotricyclic dibenzo-[24]-crown-8 ether host 52 and guests.
Figure 35: Copper imido diacetic acid azacrown receptor 53a and the suggested His-Lys binding motif; a copper ...
Figure 36: Urea (54) and thiourea (55) benzo crown receptor for transport and extraction of amino acids.
Figure 37: Crown pyryliums ion receptors 56 for amino acids.
Figure 38: Ditopic sulfonamide bridged crown ether receptor 57.
Figure 39: Luminescent peptide receptor 58.
Figure 40: Luminescent receptor 59 for the detection of D-glucosamine hydrochloride in water/ethanol and lumin...
Figure 41: Guanidinium azacrown receptor 61 for simple amino acids and ditopic receptor 62 with crown ether an...
Figure 42: Chiral bicyclic guanidinium azacrown receptor 63 and similar receptor 64 for the enantioselective t...
Figure 43: Receptors for zwitterionic species based on luminescent CEAAs.
Figure 44: 1,10-Azacrown ethers with sugar podand arms and the anticancer agent busulfan.
Figure 45: Benzo-18-crown-6 modified β-cyclodextrin 69 and β-cyclodextrin functionalized with diaza-18-crown-6...
Figure 46: Receptors for colorimetric detection of primary and secondary ammonium ions.
Figure 47: Porphyrine-crown-receptors 72.
Figure 48: Porphyrin-crown ether conjugate 73 and fullerene-ammonium ion guest 74.
Figure 49: Calix[4]arene (75a), homooxocalix[4]arene (75b) and resorcin[4]arene (75c) compared (R = H, alkyl c...
Figure 50: Calix[4]arene and ammonium ion guest (R = H, alkyl, OAcyl etc.), possible binding sites; A: co-ordi...
Figure 51: Typical guests for studies with calixarenes and related molecules.
Figure 52: Lower rim modified p-tert-butylcalix[5]arenes 82.
Figure 53: The first example of a water soluble calixarene.
Figure 54: Sulfonated water soluble calix[n]arenes that bind ammonium ions.
Figure 55: Displacement assay for acetylcholine (3) with a sulfonato-calix[6]arene (84b).
Figure 56: Amino acid inclusion in p-sulfonatocalix[4]arene (84a).
Figure 57: Calixarene receptor family 86 with upper and lower rim functionalization.
Figure 58: Calix[6]arenes 87 with one carboxylic acid functionality.
Figure 59: Sulfonated calix[n]arenes with mono-substitution at the lower rim systematically studied on their r...
Figure 60: Cyclotetrachromotropylene host (91) and its binding to lysine (81c).
Figure 61: Calixarenes 92 and 93 with phosphonic acids groups.
Figure 62: Calix[4]arene tetraphosphonic acid (94a) and a double bridged analogue (94b).
Figure 63: Calix[4]arene tetraphosphonic acid ester (92c) for surface recognition experiments.
Figure 64: Calixarene receptors 95 with α-aminophosphonate groups.
Figure 65: A bridged homocalix[3]arene 95 and a distally bridged homocalix[4]crown 96.
Figure 66: Homocalix[3]arene ammonium ion receptor 97a and the Reichardt’s dye (97b) for colorimetric assays.
Figure 67: Chromogenic diazo-bridged calix[4]arene 98.
Figure 68: Calixarene receptor 99 by Huang et al.
Figure 69: Calixarenes 100 reported by Parisi et al.
Figure 70: Guest molecules for inclusion in calixarenes 100: DAP × 2 HCl (101a), APA (101b) and Lys-OMe × 2 HC...
Figure 71: Different N-linked peptido-calixarenes open and with glycol chain bridges.
Figure 72: (S)-1,1′-Bi-2-naphthol calixarene derivative 104 published by Kubo et al.
Figure 73: A chiral ammonium-ion receptor 105 based on the calix[4]arene skeleton.
Figure 74: R-/S-phenylalaninol functionalized calix[6]arenes 106a and 106b.
Figure 75: Capped homocalix[3]arene ammonium ion receptor 107.
Figure 76: Two C3 symmetric capped calix[6]arenes 108 and 109.
Figure 77: Phosphorous-containing rigidified calix[6]arene 110.
Figure 78: Calix[6]azacryptand 111.
Figure 79: Further substituted calix[6]azacryptands 112.
Figure 80: Resorcin[4]arene (75c) and the cavitands (113).
Figure 81: Tetrasulfonatomethylcalix[4]resorcinarene (114).
Figure 82: Resorcin[4]arenes (115a/b) and pyrogallo[4]arenes (115c, 116).
Figure 83: Displacement assay for acetylcholine (3) with tetracyanoresorcin[4]arene (117).
Figure 84: Tetramethoxy resorcinarene mono-crown-5 (118).
Figure 85: Components of a resorcinarene based displacement assay for ammonium ions.
Figure 86: Chiral basket resorcin[4]arenas 121.
Figure 87: Resorcinarenes with deeper cavitand structure (122).
Figure 88: Resorcinarene with partially open deeper cavitand structure (123).
Figure 89: Water-stabilized deep cavitands with partially structure (124, 125).
Figure 90: Charged cavitands 126 for tetralkylammonium ions.
Figure 91: Ditopic calix[4]arene receptor 127 capped with glycol chains.
Figure 92: A calix[5]arene dimer for diammonium salt recognition.
Figure 93: Calixarene parts 92c and 129 for the formation molecular capsules.
Figure 94: Encapsulation of a quaternary ammonium cation by two resorcin[4]arene molecules (NMe4+@[75c]2 × Cl−...
Figure 95: Encapsulation of a quaternary ammonium cation by six resorcin[4]arene molecules (NMe3D+@[130]6 × Cl−...
Figure 96: Structure and schematic of cucurbit[6]uril (CB[6], 131a).
Figure 97: Cyclohexanocucurbit[6]uril (CB′[6], 132) and the guest molecule spermine (133).
Figure 98: α,α,δ,δ-Tetramethylcucurbit[6]uril (134).
Figure 99: Structure of the cucurbituril-phthalhydrazide analogue 135.
Figure 100: Organic cavities for the displacement assay for amine differentiation.
Figure 101: Displacement assay methodology for diammonium- and related guests involving cucurbiturils and some ...
Figure 102: Nor-seco-Cucurbituril (±)-bis-ns-CB[6] (140) and guest molecules.
Figure 103: The cucurbit[6]uril based complexes 141 for chiral discrimination.
Figure 104: Cucurbit[7]uril (131c) and its ferrocene guests (142) opposed.
Figure 105: Cucurbit[7]uril (131c) guest inclusion and representative guests.
Figure 106: Cucurbit[7]uril (131c) binding to succinylcholine (145) and different bis-ammonium and bis-phosphon...
Figure 107: Paraquat-cucurbit[8]uril complex 149.
Figure 108: Gluconuril-based ammonium receptors 150.
Figure 109: Examples of clefts (151a), tweezers (151b, 151c, 151d) and clips (151e).
Figure 110: Kemp’s triacid (152a), on example of Rebek’s receptors (152b) and guests.
Figure 111: Amino acid receptor (154) by Rebek et al.
Figure 112: Hexagonal lattice designed hosts by Bell et al.
Figure 113: Bell’s amidinium receptor (156) and the amidinium ion (157).
Figure 114: Aromatic phosphonic acids.
Figure 115: Xylene phosphonates 159 and 160a/b for recognition of amines and amino alcohols.
Figure 116: Bisphosphonate recognition motif 161 for a colorimetric assay with alizarin complexone (163) for ca...
Figure 117: Bisphosphonate/phosphate clip 164 and bisphosphonate cleft 165.
Figure 118: N-Methylpyrazine 166a, N-methylnicotinamide iodide (166b) and NAD+ (166c).
Figure 119: Bisphosphate cavitands.
Figure 120: Bisphosphonate 167 of Schrader and Finocchiaro.
Figure 121: Tweezer 168 for noradrenaline (80b).
Figure 122: Different tripods and heparin (170).
Figure 123: Squaramide based receptors 172.
Figure 124: Cage like NH4+ receptor 173 of Kim et al.
Figure 125: Ammonium receptors 174 of Chin et al.
Figure 126: 2-Oxazolin-based ammonium receptors 175a–d and 176 by Ahn et al.
Figure 127: Racemic guest molecules 177.
Figure 128: Tripods based on a imidazole containing macrocycle (178) and the guest molecules employed in the st...
Figure 129: Ammonium ion receptor 180.
Figure 130: Tetraoxa[3.3.3.3]paracyclophanes 181 and a cyclophanic tetraester (182).
Figure 131: Peptidic bridged paraquat-cyclophane.
Figure 132: Shape-selective noradrenaline host.
Figure 133: Receptor 185 for binding of noradrenaline on surface layers from Schrader et al.
Figure 134: Tetraphosphonate receptor for binding of noradrenaline.
Figure 135: Tetraphosphonate 187 of Schrader and Finocchiaro.
Figure 136: Zinc-Porphyrin ammonium-ion receptors 188 and 189 of Mizutani et al.
Figure 137: Zinc porphyrin receptor 190.
Figure 138: Zinc porphyrin receptors 191 capable of amino acid binding.
Figure 139: Zinc-porphyrins with amino acid side chains for stereoinduction.
Figure 140: Bis-zinc-bis-porphyrin based on Tröger’s base 193.
Figure 141: BINAP-zinc-prophyrin derivative 194 and it’s guests.
Figure 142: Bisaryl-linked-zinc-porphyrin receptors.
Figure 143: Bis-zinc-porphyrin 199 for diamine recognition and guests.
Figure 144: Bis-zinc-porphyrin crown ether 201.
Figure 145: Bis-zinc-porphyrin 202 for stereodiscrimination (L = large substituent; S = small substituent).
Figure 146: Bis-zinc-porphyrin[3]rotaxane and its copper complex and guests.
Figure 147: Dien-bipyridyl ligand 206 for co-ordination of two metal atoms.
Figure 148: The ligand and corresponding tetradentate co-complex 207 serving as enantioselective receptor for a...
Figure 149: Bis(oxazoline)–copper(II) complex 208 for the recognition of amino acids in aqueous solution.
Figure 150: Zinc-salen-complexes 209 for the recognition tertiary amines.
Figure 151: Bis(oxazoline)–copper(II) 211 for the recognition of amino acids in aqueous solution.
Figure 152: Zn(II)-complex of a C2 terpyridine crown ether.
Figure 153: Displacement assay and receptor for aspartate over glutamate.
Figure 154: Chiral complex 214 for a colorimetric displacement assay for amino acids.
Figure 155: Metal complex receptor 215 with tripeptide side arms.
Figure 156: A sandwich complex 216 and its displaceable dye 217.
Figure 157: Lanthanide complexes 218–220 for amino acid recognition.
Figure 158: Nonactin (221), valinomycin (222) and vancomycin (223).
Figure 159: Monesin (224a) and a chiral analogue for enantiodiscrimination of ammonium guests (224b).
Figure 160: Chiral podands (226) compared to pentaglyme-dimethylether (225) and 18-crown-6 (4).
Figure 161: Lasalocid A (228).
Figure 162: Lasalocid derivatives (230) of Sessler et al.
Figure 163: The Coporphyrin I tetraanion (231).
Figure 164: Linear and cyclic peptides for ammonium ion recognition.
Figure 165: Cyclic and bicyclic depsipeptides for ammonium ion recognition.
Figure 166: α-Cyclodextrin (136a) and novocaine (236).
Figure 167: Helical diol receptor 237 by Reetz and Sostmann.
Figure 168: Ammonium binding spherand by Cram et al. (238a) and the cyclic[6]metaphenylacetylene 238b in compar...
Figure 169: Receptor for peptide backbone and ammonium binding (239).
Figure 170: Anion sensor principle with 3-hydroxy-2-naphthanilide of Jiang et al.
Figure 171: 7-bromo-3-hydroxy-N-(2-hydroxyphenyl)naphthalene 2-carboxamide (241) and its amine binding.
Figure 172: Naturally occurring catechins with affinity to quaternary ammonium ions.
Figure 173: Spiropyran (244) and merocyanine form (244a) of the amino acid receptors of Fuji et al.
Figure 174: Coumarin aldehyde (245) and its iminium species with amino acid bound (245a) by Glass et al.
Figure 175: Coumarin aldehyde appended with boronic acid.
Figure 176: Quinolone aldehyde dimers by Glass et al.
Figure 177: Chromogenic ammonium ion receptors with trifluoroacetophenone recognition motifs.
Figure 178: Chromogenic ammonium ion receptor with trifluoroacetophenone recognition motif bound on different m...
Beilstein J. Org. Chem. 2008, 4, No. 48, doi:10.3762/bjoc.4.48
Graphical Abstract
Scheme 1: Total synthesis of longifolicin by Marshall’s group.
Scheme 2: Total synthesis of corossoline by Tanaka’s group.
Scheme 3: Total synthesis of corossoline by Wu’s group.
Scheme 4: Total synthesis of pseudo-annonacin A by Hanessian’s group.
Scheme 5: Total synthesis of tonkinecin by Wu’s group.
Scheme 6: Total synthesis of gigantetrocin A by Shi’s group.
Scheme 7: Total synthesis of annonacin by Wu’s group.
Scheme 8: Total synthesis of solamin by Kitahara’s group.
Scheme 9: Total synthesis of solamin by Mioskowski’s group.
Scheme 10: Total synthesis of cis-solamin by Makabe’s group.
Scheme 11: Total synthesis of cis-solamin by Brown’s group.
Scheme 12: The formal synthesis of (+)-cis-solamin by Donohoe’s group.
Scheme 13: Total synthesis of cis-solamin by Stark’s group.
Scheme 14: Total synthesis of mosin B by Tanaka’s group.
Scheme 15: Total synthesis of longicin by Hanessian’s group.
Scheme 16: Total synthesis of murisolin and 16,19-cis-murisolin by Tanaka’s group.
Scheme 17: Synthesis of a stereoisomer library of (+)-murisolin by Curran’s group.
Scheme 18: Total synthesis of murisolin by Makabe’s group.
Scheme 19: Total synthesis of reticulatain-1 by Makabe’s group.
Scheme 20: Total synthesis of muricatetrocin C by Ley’s group.
Scheme 21: Total synthesis of (4R,12S,15S,16S,19R,20R,34S)-muricatetrocin (146) and (4R,12R,15S,16S,19R,20R,34S...
Scheme 22: Total synthesis of parviflorin by Hoye’s group.
Scheme 23: Total synthesis of parviflorin by Trost’s group.
Scheme 24: Total synthesis of trilobacin by Sinha’s group.
Scheme 25: Total synthesis of 15-epi-annonin I 181b by Scharf’s group.
Scheme 26: Total synthesis of squamocin A and squamocin D by Scharf’s group.
Scheme 27: Total synthesis of asiminocin by Marshall’s group.
Scheme 28: Total synthesis of asiminecin by Marshall’s group.
Scheme 29: Total synthesis of (+)-(30S)-bullanin by Marshall’s group.
Scheme 30: Total synthesis of uvaricin by the group of Sinha and Keinan.
Scheme 31: Formal synthesis of uvaricin by Burke’s group.
Scheme 32: Total synthesis of trilobin by Marshall’s group.
Scheme 33: Total synthesis of trilobin by the group of Sinha and Keinan.
Scheme 34: Total synthesis of asimilobin by the group of Wang and Shi.
Scheme 35: Total synthesis of squamotacin by the group of Sinha and Keinan.
Scheme 36: Total synthesis of asimicin by Marshall’s group.
Scheme 37: Total synthesis of asimicin by the group of Sinha and Keinan.
Scheme 38: Total synthesis of asimicin by Roush’s group.
Scheme 39: Total synthesis of asimicin by Marshall’s group.
Scheme 40: Total synthesis of 10-hydroxyasimicin by Ley’s group.
Scheme 41: Total synthesis of asimin by Marshall’s group.
Scheme 42: Total synthesis of bullatacin by the group of Sinha and Keinan.
Scheme 43: Total synthesis of bullatacin by Roush’s group.
Scheme 44: Total synthesis of bullatacin by Pagenkopf’s group.
Scheme 45: Total synthesis of rollidecins C and D by the group of Sinha and Keinan.
Scheme 46: Total synthesis of 30(S)-hydroxybullatacin by Marshall’s group.
Scheme 47: Total synthesis of uvarigrandin A and 5(R)-uvarigrandin A by Marshall’s group.
Scheme 48: Total synthesis of membranacin by Brown’s group.
Scheme 49: Total synthesis of membranacin by Lee’s group.
Scheme 50: Total synthesis of rolliniastatin 1 and rollimembrin by Lee’s group.
Scheme 51: Total synthesis of longimicin D by the group of Maezaki and Tanaka.
Scheme 52: Total synthesis of the structure proposed for mucoxin by Borhan’s group.
Scheme 53: Modular synthesis of adjacent bis-THF annonaceous acetogenins by Marshall’s group.
Scheme 54: Total synthesis of 4-deoxygigantecin by Tanaka’s group.
Scheme 55: Total synthesis of squamostatins D by Marshall’s group.
Scheme 56: Total synthesis of gigantecin by Crimmins’s group.
Scheme 57: Total synthesis of gigantecin by Hoye’s group.
Scheme 58: Total synthesis of cis-sylvaticin by Donohoe’s group.
Scheme 59: Total synthesis of 17(S),18(S)-goniocin by Sinha’s group.
Scheme 60: Total synthesis of goniocin and cyclogoniodenin T by the group of Sinha and Keinan.
Scheme 61: Total synthesis of jimenezin by Takahashi’s group.
Scheme 62: Total synthesis of jimenezin by Lee’s group.
Scheme 63: Total synthesis of jimenezin by Hoffmann’s group.
Scheme 64: Total synthesis of muconin by Jacobsen’s group.
Scheme 65: Total synthesis of (+)-muconin by Kitahara’s group.
Scheme 66: Total synthesis of muconin by Takahashi’s group.
Scheme 67: Total synthesis of muconin by the group of Yoshimitsu and Nagaoka.
Scheme 68: Total synthesis of mucocin by the group of Sinha and Keinan.
Scheme 69: Total synthesis of mucocin by Takahashi’s group.
Scheme 70: Total synthesis of (−)-mucocin by Koert’s group.
Scheme 71: Total synthesis of mucocin by the group of Takahashi and Nakata.
Scheme 72: Total synthesis of mucocin by Evans’s group.
Scheme 73: Total synthesis of mucocin by Mootoo’s group.
Scheme 74: Total synthesis of (−)-mucocin by Crimmins’s group.
Scheme 75: Total synthesis of pyranicin by the group of Takahashi and Nakata.
Scheme 76: Total synthesis of pyranicin by Rein’s group.
Scheme 77: Total synthesis of proposed pyragonicin by the group of Takahashi and Nakata.
Scheme 78: Total synthesis of pyragonicin by Rein’s group.
Scheme 79: Total synthesis of pyragonicin by Takahashi’s group.
Scheme 80: Total synthesis of squamostanal A by Figadère’s group.
Scheme 81: Total synthesis of diepomuricanin by Tanaka’s group.
Scheme 82: Total synthesis of (−)-muricatacin [(R,R)-373a] and its enantiomer (+)-muricatacin [(S,S)-373b] by ...
Scheme 83: Total synthesis of epi-muricatacin (+)-(S,R)-373c and (−)-(R,S)-373d by Scharf’s group.
Scheme 84: Total synthesis of (−)-muricatacin 373a and 5-epi-(−)-muricatacin 373d by Uang’s group.
Scheme 85: Total synthesis of four stereoisomers of muricatacin by Yoon’s group.
Scheme 86: Total synthesis of (+)-muricatacin by Figadère’s group.
Scheme 87: Total synthesis of (+)-epi-muricatacin and (−)-muricatacin by Couladouros’s group.
Scheme 88: Total synthesis of muricatacin by Trost’s group.
Scheme 89: Total synthesis of (−)-(4R,5R)-muricatacin by Heck and Mioskowski’s group.
Scheme 90: Total synthesis of muricatacin (−)-373a by the group of Carda and Marco.
Scheme 91: Total synthesis of (−)- and (+)-muricatacin by Popsavin’s group.
Scheme 92: Total synthesis of (−)-muricatacin by the group of Bernard and Piras.
Scheme 93: Total synthesis of (−)-muricatacin by the group of Yoshimitsu and Nagaoka.
Scheme 94: Total synthesis of (−)-muricatacin by Quinn’s group.
Scheme 95: Total synthesis of montecristin by Brückner’s group.
Scheme 96: Total synthesis of (−)-acaterin by the group of Franck and Figadère.
Scheme 97: Total synthesis of (−)-acaterin by Singh’s group.
Scheme 98: Total synthesis of (−)-acaterin by Kumar’s group.
Scheme 99: Total synthesis of rollicosin by Quinn’s group.
Scheme 100: Total synthesis of Rollicosin by Makabe’s group.
Scheme 101: Total synthesis of squamostolide by Makabe’s group.
Scheme 102: Total synthesis of tonkinelin by Makabe’s group.
Beilstein J. Org. Chem. 2008, 4, No. 25, doi:10.3762/bjoc.4.25
Graphical Abstract
Scheme 1: Atropisomeric BINOL and conformationally restricted, (−)-fenchone-based (M)-BIFOL.
Scheme 2: Syntheses of (M)-BIMOL, (P)-BIVOL, (P)-BICOL, and (P)-BIMEOL.
Figure 1: X-Ray crystal structure of (M)-BIMOL. An acetone molecule, binding to the external OH group, is omi...
Figure 2: X-Ray crystal structure of (P)-BIVOL. A water molecule, binding to the external OH group, is omitte...
Figure 3: X-Ray crystal structure of (P)-BICOL. A water molecule, binding to the external OH group, is omitte...
Figure 4: X-Ray crystal structure of (P)-BIMEOL. An ethanol molecule, binding to the external OH group, is om...
Figure 5: B3LYP/6-31++G**:AM1 optimized structure of (M)-BIMOL, Erel. = 0.0 kcal/mol.
Figure 6: B3LYP/6-31++G**:AM1 optimized structure of (P)-BIMOL, Erel. = 1.3 kcal/mol.
Figure 7: B3LYP/6-31++G**:AM1 optimized structure of (M)-BIVOL, Erel. = 5.1 kcal/mol.
Figure 8: B3LYP/6-31++G**:AM1 optimized structure of (P)-BIVOL, Erel. = 0.0 kcal/mol.
Figure 9: B3LYP/6-31++G**:AM1 optimized structure of (M)-BICOL, Erel. = 5.8 kcal/mol.
Figure 10: B3LYP/6-31++G**:AM1 optimized structure of (P)-BICOL, Erel. = 0.0 kcal/mol.
Figure 11: B3LYP/6-31++G**:AM1 optimized structure of (M)-BIMEOL, Erel. = 5.4 kcal/mol.
Figure 12: B3LYP/6-31++G**:AM1 optimized structure of (P)-BIMEOL, Erel. = 0.0 kcal/mol.
Scheme 3: Co-solvent adducts in the X-ray structures of (M)-BIMOL, (P)-BIVOL, (P)-BICOL, and (P)-BIMEOL.
Beilstein J. Org. Chem. 2006, 2, No. 18, doi:10.1186/1860-5397-2-18
Graphical Abstract
Scheme 1: Asymmetric aza-Diels-Alder reaction of Danishefsky's diene 1 with imines 2.
Figure 1: Possible interactions of substrates or intermediate of the aza-Diels-Alder reaction with the chiral...
Beilstein J. Org. Chem. 2006, 2, No. 7, doi:10.1186/1860-5397-2-7
Graphical Abstract
Scheme 1: Pd-catalyzed allylic substitution with unsymmetrical substrates (Nu = dimethylmalonate, Nf = OAc).
Scheme 2: Bidentate P, N-ligands and a monodentate phosphoramidite for Pd-catalyzed allylic substitutions wit...
Scheme 3: Fenchole-based phosphorus ligands (i.e. FEENOPs and BIFOPs) for Pd-catalyzed allylic substitutions....
Scheme 4: Allylic alkylation of 1-phenyl-2-propenyl acetate by sodium dimethylmalonate (BSA-method) with Pd-F...
Figure 1: X-ray crystal structure of the cationic complex Pd-FENOP (CCDC 299944), the perchlorate counterion ...
Figure 2: X-ray crystal structure of the cationic complex Pd-FENOP-Me (CCDC 600369), the perchlorate counteri...
Figure 3: X-ray crystal structure of the cationic complex Pd-FENOP-NMe2 (CCDC 600370), the perchlorate counte...
Figure 4: The two most stable ONIOM(B3LYP/SDD(+ECP) (Pd) /6-31G* (C, H, O, N, P) : UFF) optimized transition ...
Figure 5: The two most stable ONIOM(B3LYP/SDD(+ECP) (Pd) /6-31G* (C, H, O, N, P) : UFF) optimized transition ...